Acurx Pharmaceuticals Secures New Patent for Innovative DNA Polymerase IIIC Inhibitors Acurx Pharmaceuticals has been granted a new patent for DNA Polymerase IIIC inhibitors, enhancing its portfolio in antibiotic development and treatment for severe bacterial infections.

Acurx Pharmaceuticals Secures New Patent for Innovative DNA Polymerase IIIC Inhibitors #United_States #Staten_Island #Acurx_Pharmaceuticals #Antibiotic_Development #DNA_Polymerase_IIIC

Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates Acurx Pharmaceuticals delivers an encouraging financial report for Q1 2025, highlighting advancements in antibiotic development and strategic partnerships.

Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates #USA #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #Antibiotic_Development

Acurx Pharmaceuticals Secures $2.5 Million in Direct Stock Offering Amid Development of New Antibiotic Class Acurx Pharmaceuticals has successfully closed a $2.5 million direct offering of its common stock, designed to fund the development of innovative antibiotics targeting resistant bacterial infections.

Acurx Pharmaceuticals Secures $2.5 Million in Direct Stock Offering Amid Development of New Antibiotic Class #United_States #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #Antibiotic_Development